Briacell Therapeutics
BCTX
18 hedge funds and large institutions have $10.9M invested in Briacell Therapeutics in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 8 closing their positions.
157% more call options, than puts
Call options by funds: $11.9M | Put options by funds: $4.62M
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
129% more capital invested
Capital invested by funds: $4.77M → $10.9M (+$6.14M)
0.03% more ownership
Funds ownership: 0.03% → 0.06% (+0.03%)
5% less funds holding
Funds holding: 19 → 18 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voloridge Investment Management
Jupiter,
Florida
|
+$406K |
| 2 |
IA
Insight Advisors
Newtown,
Pennsylvania
|
+$148K |
| 3 |
CWP
Concord Wealth Partners
Abingdon,
Virginia
|
+$111K |
| 4 |
TCWM
Total Clarity Wealth Management
St. Charles,
Illinois
|
+$38K |
| 5 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
+$31.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$503K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$326K |
| 3 |
Jane Street
New York
|
-$308K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
-$119K |
| 5 |
GG
Gofen & Glossberg
Chicago,
Illinois
|
-$81K |
BCTX Hedge Fund Activity: Q4 2021 in Review
18 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q4 2021, worth a combined $10.9M — up 129% from $4.77M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BCTX and 7 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 7 added.
The largest buyer was Voloridge Investment Management, adding an estimated $406K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $503K sold.
- 18 institutional investors held Briacell Therapeutics (BCTX) as of Q4 2021, down from 19 in Q3 2021.
- Funds reported $10.9M of Briacell Therapeutics stock for Q4 2021, up 129% quarter-over-quarter.
- 7 funds opened new Briacell Therapeutics positions in Q4 2021 and 8 closed out, a net change of -1 holder.
- The largest Briacell Therapeutics buyer in Q4 2021 was Voloridge Investment Management, an estimated $406K added.
- The largest Briacell Therapeutics seller in Q4 2021 was Two Sigma Investments, an estimated $503K sold.
Based on aggregated 13F filings for Q4 2021.